Results 61 to 70 of about 4,766 (189)

Consensus HIV-1 FSU-A integrase gene variants electroporated into mice induce polyfunctional antigen-specific CD4+ and CD8+ T cells. [PDF]

PLoS ONE, 2013
Our objective is to create gene immunogens targeted against drug-resistant HIV-1, focusing on HIV-1 enzymes as critical components in viral replication and drug resistance. Consensus-based gene vaccines are specifically fit for variable pathogens such as
Olga Krotova, Elizaveta Starodubova, Stefan Petkov, Linda Kostic, Julia Agapkina, David Hallengärd, Alecia Viklund, Oleg Latyshev, Eva Gelius, Tomas Dillenbeck, Vadim Karpov, Marina Gottikh, Igor M Belyakov, Vladimir Lukashov, Maria G Isaguliants   +14 more
doaj   +1 more source

Major revision version 13.0 of the European AIDS Clinical Society guidelines 2025

HIV Medicine, Volume 27, Issue 1, Page 18-32, January 2026.
Abstract Background The European AIDS Clinical Society (EACS) guidelines were revised for the 21st time in 2025, with updates covering all aspects of HIV care. Key Points of the Guidelines Update The structure of the guidelines has been reorganized into two parts: Part I focuses on the management and prevention of HIV and related infections, and Part ...
Juan Ambrosioni, Laura I. Levi, Jasmini Alagaratnam, Abiu Sempere, Andrea Mastrangelo, Paolo Paioni, Cristina Mussini, Catia Marzolini, Susanne Dam Nielsen, Charles Béguelin, Steven Welch, Anna Koval, Luis Mendao, Alasdair Bamford, Alexandra Calmy, Giovanni Guaraldi, Cristiana Oprea, Esteban Martínez, Jürgen K. Rockstroh, The EACS Governing Board   +19 more
wiley   +1 more source

Will Drug Resistance against Dolutegravir in Initial Therapy Ever Occur?

Frontiers in Pharmacology, 2015
Dolutegravir (DTG) is a second-generation integrase strand transfer inhibitor (INSTI) and INSTIs are the latest class of potent anti-HIV drugs. Compared to the first generation INSTIs, raltegravir (RAL) and elvitegravir (EVG), DTG shows a limited cross ...
Mark eWainberg, Yingshan eHan
doaj   +1 more source

Impact on weight of a Doravirine switch in people living with HIV

HIV Medicine, Volume 27, Issue 1, Page 136-145, January 2026.
Abstract Background and Objective Doravirine is among the first‐line recommended treatments for people living with HIV (PLHIV) in the 2025 EACS guidelines. As opposed to tenofovir alafenamide or anti‐integrase, its use was not associated with weight gain in clinical trials, but limited data are currently available in real life. In this cohort study, we
Nina Garofoli, Philippe Flandre, Jean‐Paul Vincensini, Quentin Richier, Priscille Couture, Karine Lacombe, Gilles Pialoux, Jean‐Luc Meynard   +7 more
wiley   +1 more source

HIV integrase inhibitor, Elvitegravir, impairs RAG functions and inhibits V(D)J recombination

, 2017
Integrase inhibitors are a class of antiretroviral drugs used for the treatment of AIDS that target HIV integrase, an enzyme responsible for integration of viral cDNA into host genome.
Monica Pandey, Mayilaadumveettil Nishana, Namrata M Nilavar, Nilavar, Namrata M, Sathees C Raghavan, Nishana, Mayilaadumveettil, Kumari, Rupa, Rupa Kumari, Pandey, Monica, Raghavan, Sathees C   +9 more
core   +1 more source

Effect of Ethanol on the Metabolic Characteristics of HIV-1 Integrase Inhibitor Elvitegravir and Elvitegravir/Cobicistat with CYP3A: An Analysis Using a Newly Developed LC-MS/MS Method. [PDF]

PLoS ONE, 2016
Elvitegravir (EVG), an integrase inhibitor for the treatment HIV infection, is increasingly becoming the part of first-line antiretroviral therapy (ART) regimen. EVG is mainly metabolized through cytochrome P450 (CYP) 3A4.
Narasimha M Midde, Mohammad A Rahman, Chetan Rathi, Junhao Li, Bernd Meibohm, Weihua Li, Santosh Kumar   +6 more
doaj   +1 more source

NEW ANALYTICAL METHOD VALIDATION REPORT AND FORCED DEGRADATION STUDIES FOR ASSAY OF ELVITEGRAVIR, TENOFOVIR, EMTRICITABINE AND COBICISTAT BY RP-UPLC

, 2017
The main aim of the present work is to develop and validate a simple, specific, efficient, accurate, and precise stability-indicating rapid reversed phase ultra performance liquid chromatographic method is developed for the simultaneous determination of ...
K. Kranthi Kiran*, Dr. A. Srinivasa Rao, Prof. D. Gowri Sankar
core   +1 more source

Comparable real‐world effectiveness between switches to cabotegravir + rilpivirine long‐acting or modern daily oral regimens in the United States: an OPERA cohort study

Journal of the International AIDS Society, Volume 28, Issue 12, December 2025.
Abstract Introduction Cabotegravir + rilpivirine long‐acting (CAB+RPV LA) injectable was approved in the United States in 2021 for HIV‐1 treatment in virologically suppressed (viral load [VL] <50 copies/mI individuals. In clinical trials, CAB+RPV LA was non‐inferior to oral antiretroviral therapy (ART) regimens in virologically suppressed individuals ...
Ricky K. Hsu, Michael G. Sension, Jennifer S. Fusco, Laurence Brunet, Quateka Cochran, Brooke Levis, Gayathri Sridhar, Vani Vannappagari, Jean Van Wyk, Michael B. Wohlfeiler, Gregory P. Fusco   +10 more
wiley   +1 more source

Resistance to Integrase Inhibitors

Viruses, 2010
Integrase (IN) is a clinically validated target for the treatment of human immunodeficiency virus infections and raltegravir exhibits remarkable clinical activity. The next most advanced IN inhibitor is elvitegravir.
Mathieu Métifiot, Christophe Marchand, Kasthuraiah Maddali, Yves Pommier   +3 more
doaj   +1 more source

Liquid–Liquid Phase Separation: Mechanisms, Roles, and Implications in Cellular Function and Disease

FASEB BioAdvances, Volume 7, Issue 11, November 2025.
Liquid–liquid phase separation (LLPS) is a fundamental biophysical process responsible for forming membraneless organelles involved in key cellular functions like chromatin organization and gene expression. Dysregulation of LLPS contributes to various diseases, including neurodegenerative disorders.
Dikesh Kumar Thakur, Sonal Padole, Tapati Sarkar, Somasundaram Arumugam, Shiladitya Chattopadhyay   +4 more
wiley   +1 more source